Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been utilized for cancer therapy, but the resistance of cancer cells to TRAIL remains an obstacle. Ether à go-go 1 (Eag1) channel is overexpressed in a variety of cancers and implicated in tumor progression. However, the therapeutic potential of Eag1 in osteosarcoma remains elusive. In this study, we generated CRAd5.TRAIL/siEag1 adenoviral vector that permitted simultaneous knockdown of Eag1 and overexpression of TRAIL and investigated its antitumor effects on human osteosarcoma MG-63 cells. Our results showed that CRAd5.TRAIL/siEag1 induced growth arrest and apoptosis of MG-63 cells in a more efficient manner than CRAd5.TRAIL or CRAd5.siEag1, and had no effect on human osteoblastic hFOB 1.19 cells. Furthermore, treatment of an osteosarcoma xenograft model with CRAd5.TRAIL/siEag1 resulted in significant tumor regression and cancer cell apoptosis, compared with treatment with CRAd5.TRAIL or CRAd5.siEag1. Taken together, our results demonstrate that CRAd5.TRAIL/siEag1 may represent an effective strategy for osteosarcoma gene therapy due to the synergistic antitumor effects of Eag1 knockdown and TRAIL overexpression.
Get full access to this article
View all access options for this article.
References
1.
DamronTA, WardWG, StewartA. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National cancer data base report. Clin Orthop Relat Res, 2007; 459:40.
2.
SlugaM, WindhagerR, PfeifferMet al.Osteosarcoma and Ewing's sarcoma-The most frequent malignant bone tumors in children-therapy and outcome. Z Orthop Ihre Grenzgeb, 2002; 140:652.
3.
KleinMJ, SiegalGP. Osteosarcoma: Anatomic and histologic variants. Am J Clin Pathol, 2006; 125:555.
4.
BenayahuD, ShurI, MaromRet al.Cellular and molecular properties associated with osteosarcoma cells. J Cell Biochem, 2001; 84:108.
5.
Panizo-SantosA, SolaI, LozanoMet al.Metastatic osteosarcoma presenting as a small bowel polyp: A case report and review of the literature. Arch Pathol Lab Med, 2000; 124:1682.
6.
HawkinsDS, ArndtCA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer, 2003; 98:2447.
7.
WuPK, ChenWM, ChenCFet al.Primary osteogenic sarcoma with pulmonary metastasis: Clinical results and prognostic factors in 91 patients. Jpn J Clin Oncol, 2009; 39:514.
8.
HemmerleinB, WeselohRM, Mello de QueirozFet al.Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer, 2006; 5:41.
9.
DingXW, LuoHS, JinXet al.Aberrant expression of Eag1 potassium channels in gastric cancer patients and cell lines. Med Oncol, 2007; 24:345.
10.
AgarwalJR, GriesingerF, StühmerWet al.The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia. Mol Cancer, 2010; 9:18.
11.
Mello de QueirozF, Suarez-KurtzG, StühmerWet al.Ether à go-go potassium channel expression in soft tissue sarcoma patients. Mol Cancer, 2006; 5:42.
12.
WeberC, Mello de QueirozF, DownieBRet al.Silencing the activity and proliferative properties of the human EagI Potassium Channel by RNA Interference. J Biol Chem, 2006; 281:13030.
13.
PardoLA, Del CaminoD, SánchezAet al.Oncogenic potential of EAG K+ channels. EMBO J, 1999; 18:5540.
14.
PittiRM, MarstersSA, RuppertSet al.Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem, 1996; 271:12687.
15.
WalczakH, MillerRE, AriailKet al.Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med, 1999; 5:157.
16.
JaganathanJ, PetitJH, LazioBEet al.Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines. Neurosurg Focus, 2002; 13:ecp1.
17.
EngelJB, MartensT, HahneJCet al.Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anticancer Drugs, 2012; 23:426.
18.
ClarkPE, PolosukhinaDA, GyabaahKet al.TRAIL and interferon-alpha act synergistically to induce renal cell carcinoma apoptosis. J Urol, 2010; 184:1166.
19.
MatsuiTA, SowaY, YoshidaTet al.Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis, 2006; 27:1768.
20.
BouralexisS, FindlayDM, AtkinsGJet al.Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: Resensitisation with chemotherapy. Br J Cancer, 2003; 89:206.
21.
SeolJY, ParkKH, HwangCIet al.Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther, 2003; 10:540.
22.
YangF, ShiP, XiXet al.Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC)Med Oncol, 2006; 23:191.
23.
ArmeanuS, LauerUM, SmirnowIet al.Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res, 2003; 63:2369.
24.
HavivYS. A simplified in vitro ligation approach to clone an E1B55k-deleted double-targeted conditionally-replicative adenovirus. Virol J, 2009; 6:18.
25.
GaoYS, MeiJ, TongTLet al.Inhibitory effects of VEGF-siRNA mediated by adenovirus on osteosarcoma-bearing nude mice. Cancer Biother Radiopharm, 2009; 24:243.
26.
TruccoC, OliverFJ, de MurciaGet al.DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res, 1998; 26:2644.
27.
D'AmoursD, GermainM, OrthKet al.Proteolysis of poly(ADP-ribose) polymerase by caspase 3: Kinetics of cleavage of mono(ADP-ribosyl)ated and DNA-bound substrates. Radiat Res, 1998; 150:3.
28.
GermainM, AffarEB, D'AmoursDet al.Cleavage of automodified poly(ADP-ribose) polymerase during apoptosis. Evidence for involvement of caspase-7. J Biol Chem., 1999; 274:28379.
29.
WarmkeJW, GanetzkyB. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci U S A, 1994; 91:3438.
